中国全科医学2026，Vol.29Issue(6)：688-692,5.DOI:10.12114/j.issn.1007-9572.2024.0616
基于《2024年意大利共识:慢性阻塞性肺疾病的三联吸入治疗》对中国慢性阻塞性肺疾病患者管理的启示
Implications for the Management of Chronic Obstructive Pulmonary Disease Patients Based on the Italian Consensus in 2024:Triple Inhalation Therapy in Chronic Obstructive Pulmonary Disease
摘要
Abstract
In China,chronic obstructive pulmonary disease(COPD)is a prevalent chronic disorder.With high incidence and mortality,it burdens both individual health and socioeconomic systems.Pharmacological treatment is essential for COPD management,and personalized therapy is key.Triple therapy combining inhaled corticosteroids(ICS),long-acting muscarinic antagonist(LAMA),and long-acting beta-agonist(LABA)has become a focal point.In 2024 Italy has refined the management of COPD patients through the establishment of an expert panel focusing on the applicability of triple therapy in order to standardize the management of patients with COPD and published the"An Italian Delphi Consensus on the Triple Inhalation Therapy in Chronic Obstructive Pulmonary Disease".This article interprets the consensus'core points on triple therapy,analyzes its applications in diverse clinical scenarios,and provides evidence-based guidance for optimizing drug selection in Chinese COPD treatment.The goal is to improve treatment standardization and enhance patient outcomes.关键词
肺疾病,慢性阻塞性/三联疗法/共识/疾病管理Key words
Pulmonary disease,chronic obstructive/Triple therapy/Consensus/Disease management分类
医药卫生引用本文复制引用
陈楚萍,廖晓阳,雷弋,刘力滴,杨梓钰,张鹏,张瑞,袁波,沈灿,杨荣,李东泽..基于《2024年意大利共识:慢性阻塞性肺疾病的三联吸入治疗》对中国慢性阻塞性肺疾病患者管理的启示[J].中国全科医学,2026,29(6):688-692,5.基金项目
四大慢病重大专项(2023ZD0506101,2023ZD0506100) （2023ZD0506101,2023ZD0506100）
国家临床重点专科建设项目(川卫医政函[2023]87号) （川卫医政函[2023]87号）
